SELECT: Novo Nordisk Comes Roaring Back

After being whipped repeatedly by Lilly’s Mounjaro, Novo’s Wegovy smashes its obesity cardiovascular outcomes trial.

Two months ago, analysts regarded a 20% reduction in cardiovascular events among obesity patients as the best-case scenario for Novo Nordisk A/S’s Wegovy (semaglutide injection 2.4mg). Today the vast SELECT trial hit that bullseye, driving Novo’s shares up by 18% to DKK1,285.60 ($188.67) as investors anticipate wider reimbursement and a further leap in demand.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

US FDA Expands Label For BMS’s Camzyos Days After Phase III Stumble

18 Apr 2025

• By Alaric DeArment

The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.

Camzyos nHCM Failure Could Open Door To Threat From Cytokinetics’ Aficamten

15 Apr 2025

• By Alaric DeArment

BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.

Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly

15 Apr 2025

• By Andy Smith

The end of the American College of Cardiology conference was a prelude to a volatile trading week for most stocks. Even before Liberation Day, reactions to the conference announcements were not encouraging.